Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Short-term Investments: 2009-2022

Historic Short-term Investments for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Dec 2022 value amounting to $1.3 million.

  • Ironwood Pharmaceuticals' Short-term Investments fell 36.96% to $788,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $788,000, marking a year-over-year decrease of 36.96%. This contributed to the annual value of $1.3 million for FY2022, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2022, Ironwood Pharmaceuticals' Short-term Investments is $1.3 million, which was down 0.00% from $1.3 million recorded in FY2021.
  • Ironwood Pharmaceuticals' 5-year Short-term Investments high stood at $1.7 million for FY2020, and its period low was $1.2 million during FY2018.
  • Its 3-year average for Short-term Investments is $1.4 million, with a median of $1.3 million in 2022.
  • In the last 5 years, Ironwood Pharmaceuticals' Short-term Investments plummeted by 98.69% in 2018 and then skyrocketed by 38.80% in 2020.
  • Over the past 5 years, Ironwood Pharmaceuticals' Short-term Investments (Yearly) stood at $1.2 million in 2018, then remained steady at $1.2 million in 2019, then spiked by 38.80% to $1.7 million in 2020, then fell by 25.07% to $1.3 million in 2021, then remained steady at $1.3 million in 2022.